ILD (IIP, non-IIP, sarcoidosis), PCP and control subgroups used for analysis
| IIP (n=5) | |
| Age, year (mean±SD) | 54.6±22.8 |
| Sex, male (n) | 2 |
| Immunosuppressive therapy (n) | 2 |
| Detailed diagnosis | IPF(2), UIP (2), COP (1), |
| FEV1% (range; mean±SD) | 40–108; 74.8±24.5 |
| FVC % (range; mean±SD) | 42–118; 77.4±29.5 |
| TLC % (range; mean±SD) | 43–104; 76.2±27.8 |
| Non-IIP (n=6) | |
| Age, year (mean±SD) | 56.0±17.9 |
| Sex, male (n) | 5 |
| Immunosuppressive therapy (n) | 3 |
| Detailed diagnosis | RA (1), asbestosis (1), EP (3), EAA (1) |
| FEV1% (range; mean±SD) | 55–75; 65.5±8.2 |
| FVC % (range; mean±SD) | 58–85; 74.2±11.7 |
| TLC % (range; mean±SD)* | 52–94; 76.0±16.0 |
| Sarcoidosis (n=7) | |
| Age, year (mean±SD) | 48.5±6.5 |
| Sex, male (n) | 6 |
| Immunosuppressive therapy (n) | 1 |
| FEV1% (range; mean±SD) | 60–136; 91.4±26.1 |
| FVC % (range; mean±SD) | 65–131; 99.6±28.1 |
| TLC % (range; mean±SD) | 59–122; 94.0±21.6 |
| Pneumocystis pneumonia (PCP) (n=6) | |
| Age, year (mean±SD) | 58.3±10.6 |
| Sex, male (n) | 5 |
| Immunosuppressive therapy (n) | 6 |
| FEV1% (range; mean±SD)† | 56–101; 80.8±19.6 |
| FVC % (range; mean±SD) † | 52–115; 84.0±23.0 |
| Normal controls (n=9) | |
| Age, year (mean±SD) | 57.6±11.4 |
| Sex, male (n) | 6 |
| Immunosuppressive therapy (n) | 0 |
*No TLC data available for patient (ID 12).
†No lung function data available for patient (ID 25) with Pneumocystis pneumonia.
COP, cryptogenic organising pneumonia; EAA, exogenous allergic alveolitis; EP, eosinophilic pneumonia; FEV1%, forced expiratory volume in 1 s as a percentage of the predicted value; FVC %, forced vital capacity as a percentage of the predicted value; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; non-IIP, non-idiopathic interstitial pneumonia; RA, rheumatoid arthritis; TLC %, total lung capacity as a percentage of the predicted value; UIP, usual interstitial pneumonia.